Syn-Coll vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- Extended (lipid depot in stratum corneum)
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- Topical
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- Once or twice daily
- 3 consecutive days per cycle
- Key Benefits
- Directly activates TGF-beta for potent collagen synthesis stimulation
- Increases dermal thickness and firmness
- Reduces depth of wrinkles and fine lines
- Improves skin elasticity
- Clinically validated in collagen induction studies
- Complementary to retinoids or vitamin C
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Generally well-tolerated
- Rare mild irritation at high concentrations
- Possible sensitivity in individuals with inflammatory skin conditions
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —